Shanghai InnoStar Bio-tech Co Supply Chain
Supply Chain of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 16, 2026.
Get this data via API
Financial Data API
Supply Chain
-
Last updated:
Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Shanghai InnoStar Bio-tech Co Stock analysis
What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd is a company based in Shanghai, China, operating within the Life Sciences Tools & Services sector of the Health Care industry. The company has 1,085 employees and completed its initial public offering (IPO) on September 3, 2024. It provides biopharmaceutical non-clinical research services, focusing on early drug development evaluation, non-clinical research, and clinical testing and translational research. The early drug development evaluation involves creating multiple early toxicity rapid prediction and screening models. Non-clinical research encompasses safety evaluation, pharmacokinetic research, and pharmacodynamic research. Clinical testing and translational research offers analytical methods and data support for clinical pharmacokinetics, efficacy, and safety studies related to innovative drug projects. The company's headquarters are located in Shanghai, and it maintains a website at www.innostar.cn. Its stock is listed under the ticker 688710.SS with ISIN CNE1000078J7. Shanghai InnoStar Bio-tech Co Ltd serves the biopharmaceutical sector by supporting the development and evaluation of new drugs through specialized research services. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.
All Key Metrics — Shanghai InnoStar Bio-tech Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth